Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the impressive results reported, such as the 73% overall response rate and the well-tolerated nature of larotrectinib. The use of phrases like 'needle in a haystack, but if you find it - it’s a golden needle' indicates a strong appreciation for the drug's potential, while references to conferences underscore the excitement and importance of the findings in the medical community.
The majority of discussions reflect strong support for the findings of the publication, indicating consensus among many participants.
There is a high level of curiosity, as many participants express enthusiasm towards the advances in treating TRK fusion-positive lung cancers.
While some discussions delve into specifics regarding methodology and results, the overall engagement is moderate, showing some depth but not extensive.
Participants generally perceive the publication as having a significant impact on treatment options and patient care in oncology.
Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4mo; mOS 40.7mo NTRK may be a needle in a haystack, but if u find it- it’s a golden needle
"Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluable patients ORR: 73% mDOR: 33.9 months, mPFS: 35.4 months mOS: 40.7 months Good CNS activity @OncoAlert https://t.co/Qzhfyhj6XU https://t.co/Sr0gf37snL
.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. https://t.co/HoQ25G6mgw https://t.co/VgpIkLa9jM
Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md OS 40.7 months #LCSM @OncoAlert https://t.co/GOPqxbgHZi
An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in patients with TRK fusion-positive #lungcancers, including those with #SNC #metastases. https://t.co/LmgOkxSL2D https://t.co/w6jI7poYlL
Larotrectinib is an effective treatment for lung cancers with TRK gene fusions, demonstrating a 73% response rate. This video discusses the findings of clinical trials and emphasizes the importance of testing for TRK…
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer www.sciencedirect.com/science/arti... #hvhebron #onco [Text complet]
RT @MGHCancerCenter: #ASCO23 | Hall A | Sunday 8am CT Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor…
#ASCO23 | Hall A | Sunday 8am CT Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer Jessica Lin, MD (@JessicaJLinMD) ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 https://t.co/OIbGxHfYrW
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @Dr_Ivanoncologo: An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in pa…
RT @Dr_Ivanoncologo: An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in pa…
RT @Dr_Ivanoncologo: An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in pa…
RT @Dr_Ivanoncologo: An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in pa…
#WCGIC2022 is approaching! 2nd July @ElenaGarralda will discuss the long-term efficacy and safety of #larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion GI cancers #MedEd #NTRK #Oncology https://t.co/IpoHoMW09E
RT @Dr_Ivanoncologo: An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in pa…
An interesting review shows that the highly selective #TRK inhibitor #larotrectinib is active and well-tolerated in patients with TRK fusion-positive #lungcancers, including those with #SNC #metastases. https://t.co/LmgOkxSL2D https://t.co/w6jI7poYlL
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
#ASCO22 – June 6, 2:11 PM CT, Hall D1, poster 12: former LCRF grantee Dr. Alexander Drilon will present a poster session on updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion #lungcancer. https://t.co/QbXd5vao9o https://t.co/oWmoQZxnwd
@alexdrilon @JessicaJLinMD Read the full study at: https://t.co/ghj3rXOWOi
While TRK inhibitors are a pan-cancer therapy for tumors with TRK fusions, this paper summarizes efficacy in fusion-positive lung cancer. PFS of 35 months and OS 41 months with good results also seen in patients with CNS mets. We should never miss these https://t.co/zaQ5hrQCPT
RT @cancer_evolve: LUNG: in a small study of patients with advanced NTRK fusion positive tumours who had failed conventional therapy, the N…
LUNG: in a small study of patients with advanced NTRK fusion positive tumours who had failed conventional therapy, the NTRK inhibitor larotrectinib delivered ORR 73% for 15 patients treated, including 1 complete response. https://t.co/TT2PycaotL
RT @RManochakian:
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. https://t.co/HoQ25G6mgw https://t.co/VgpIkLa9jM
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
RT @ADesaiMD: "Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluab…
"Efficacy and Safety of #Larotrectinib in Patients With #TRK–Positive Lung Cancers" @JCOPO_ASCO @alexdrilon among 15 evaluable patients ORR: 73% mDOR: 33.9 months, mPFS: 35.4 months mOS: 40.7 months Good CNS activity @OncoAlert https://t.co/Qzhfyhj6XU https://t.co/Sr0gf37snL
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
RT @dipeshuprety4: Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md…
Safety and efficacy of Larotrectinib --> NTRK-fusion positive NSCLC cohort --> ORR 73% Md DOR 33.9 mo Md PFS 35.4 mo Md OS 40.7 months #LCSM @OncoAlert https://t.co/GOPqxbgHZi
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
RT @DrJNaidoo: Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4…
Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4mo; mOS 40.7mo NTRK may be a needle in a haystack, but if u find it- it’s a golden needle
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
New article: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers https://t.co/46qmuoiWJu #lungcancer #oncology https://t.co/NxaXaqT6DA
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
RT @StephenVLiu: Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 7…
WATCH: @alexdrilon, of @sloan_kettering, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 meeting. #WCLC21 #lcsm https://t.co/UJVXw0sH3u https://t.co/MHKK3XxL8u
SO-29: Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive gastrointestinal (GI) cancer: an expanded dataset talk by Valentina Boni #WorldGI2021 @myESMO #CRCSM https://t.co/OArOi9Hg1w